Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Van Cutsem

Showing results (151-160 of 251) with videos related to

Pageof 26
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2015
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patientsE Van Cutsem, H Prenen, G D'Haens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation studyR K Kelley, C Verslype, A L Cohn, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2004
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancerJ M Blazeby, T Conroy, A Bottomley, et al.
British Journal of Cancer|March 10, 2005
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II studyE Van Cutsem, L Dirix, J-L Van Laethem, et al.
Annals of Surgery|November 23, 2000
Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomyT Lerut, P Flamen, N Ectors, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2007
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabW De Roock, H Piessevaux, J De Schutter, et al.
British Journal of Cancer|November 28, 2007
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumabS Siena, M Peeters, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyE Van Cutsem, S Siena, Y Humblet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2014
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)F Ciardiello, D Arnold, P G Casali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II studyE Van Cutsem, M Findlay, B Osterwalder, et al.
Pageof 26

Showing results (151-160 of 251) with videos related to

Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2015
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patientsE Van Cutsem, H Prenen, G D'Haens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation studyR K Kelley, C Verslype, A L Cohn, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2004
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancerJ M Blazeby, T Conroy, A Bottomley, et al.
British Journal of Cancer|March 10, 2005
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II studyE Van Cutsem, L Dirix, J-L Van Laethem, et al.
Annals of Surgery|November 23, 2000
Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomyT Lerut, P Flamen, N Ectors, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2007
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabW De Roock, H Piessevaux, J De Schutter, et al.
British Journal of Cancer|November 28, 2007
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumabS Siena, M Peeters, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyE Van Cutsem, S Siena, Y Humblet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2014
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)F Ciardiello, D Arnold, P G Casali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II studyE Van Cutsem, M Findlay, B Osterwalder, et al.
Pageof 26